Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge

Highlights • A recombinant modified Vaccinia Ankara virus expressing VP2 of African horse sickness virus serotype 9 was generated. • Four horses were vaccinated on days 0 and 20. Three unvaccinated controls were used. • Vaccinated and control horses were challenged intravenously with 107.4 TCID50 of...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2014-06, Vol.32 (29), p.3670-3674
Main Authors: Alberca, Berta, Bachanek-Bankowska, Katarzyna, Cabana, Marta, Calvo-Pinilla, Eva, Viaplana, Elisenda, Frost, Lorraine, Gubbins, Simon, Urniza, Alicia, Mertens, Peter, Castillo-Olivares, Javier
Format: Article
Language:English
Subjects:
African horse sickness
African Horse Sickness - prevention & control
African horse sickness virus
Allergy and Immunology
Animals
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Applied microbiology
Biological and medical sciences
capsid
Capsid Proteins - immunology
coat proteins
Disease
Equidae
Female
Fundamental and applied biological sciences. Psychology
genes
Horses
Horses - immunology
Infections
interferon-alpha
Male
mice
Microbiology
Miscellaneous
Modified vaccinia Ankara
Mortality
neutralization
Neutralization Tests
neutralizing antibodies
pathogens
Protection
Proteins
serotypes
vaccination
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Synthetic - immunology
Vaccinia virus
Vaccinia virus - genetics
Viral Vaccines - immunology
viremia
Viremia - prevention & control
Virology
virulence
virulent strains
Viruses
VP2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • A recombinant modified Vaccinia Ankara virus expressing VP2 of African horse sickness virus serotype 9 was generated. • Four horses were vaccinated on days 0 and 20. Three unvaccinated controls were used. • Vaccinated and control horses were challenged intravenously with 107.4 TCID50 of AHSV-9 on day 34 of the study. • At challenge, vaccinates had virus neutralising antibodies but were negative for antibodies to AHSV-VP7. • All vaccinates were completely protected against clinical signs of African horse sickness.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.04.036